Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis

被引:12
|
作者
Zhang, Haiguang [1 ]
Ge, Junbo [1 ]
Hong, Huanyu [1 ]
Bi, Lili [2 ]
Sun, Zhengwen [1 ]
机构
[1] Yantaishan Hosp, 91 Jiefang Rd, Yantai 264000, Shandong, Peoples R China
[2] Yeda Hosp, Yantai 264000, Shandong, Peoples R China
来源
关键词
ERCC1; ERCC2; Chemotherapy response; Polymorphism; Meta-analysis; FILE-DRAWER PROBLEM; MOLECULAR PATHOGENESIS; SURVIVAL; PATHWAY; VARIABILITY; STRATEGIES; CANCER; GLIOMA; RISK; AGE;
D O I
10.1186/s12957-017-1142-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: There existed controversies about the association between the response to chemotherapy for osteosarcoma (OS) patients and the genetic polymorphisms in excision repair cross-complementation group (ERCC1 and ERCC2) genes. We aimed to perform a meta-analysis to comprehensively evaluate the association. Method: We searched multiple databases for literature retrieval including the PubMED (1966 similar to 2017), Embase (1980 similar to 2017), and the Web of science (1945 similar to 2017). The overall odds ratios(OR) and their corresponding 95% confidence interval (CI) were calculated for the three polymorphisms under the dominant, recessive, and allelic models. Results: From six eligible articles in our study, we found that for ERCC1 rs11615 polymorphism, a significant association was detected between the chemotherapy response and the polymorphism under all three models (dominant model: OR = 2.015, P = 0.005; recessive model: OR = 1.791, P = 0.003; allelic model: OR = 1.677, P = 0.003), and OS patients carrying C allele in rs11615 polymorphism were more likely to response to chemotherapy. In terms of ERCC2 rs1799793 polymorphism, this polymorphism was significantly associated with the response to chemotherapy for OS patients under recessive model (OR = 1.337, P = 0.036), and patients with AG + AA genotype in rs1799793 polymorphism were more appropriate to receive chemotherapy. With respect to ERCC2 rs13181 polymorphism, this polymorphism was not correlated with the response to chemotherapy for OS patients under all three models. Conclusions: Our meta-analysis suggested that among Chinese population, the rs11615 and rs1799793 polymorphisms were significantly correlated with the response to chemotherapy for patients with OS, and patients with CC or TC + CC genotypes in ERCC1 rs11615 polymorphism or AG + AA genotype in ERCC2 rs1799793 polymorphism were more suitable for chemotherapy.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Polymorphisms in the ERCC1 and XPF Genes and Risk of Breast Cancer in a Chinese Population
    Yang, Zecheng
    Fang, Xuedong
    Pei, Xinhong
    Li, Huixiang
    [J]. GENETIC TESTING AND MOLECULAR BIOMARKERS, 2013, 17 (09) : 700 - 706
  • [32] Constitutive polymorphisms in DNA repair genes ERCC1, ERCC2, XRCC1, and MGMT in adults with glioma and controls
    Wrensch, M
    Kelsey, KT
    Liu, M
    Miike, R
    Moghadassi, M
    Aldape, K
    McMillan, A
    Wiemels, J
    Wiencke, JK
    [J]. NEURO-ONCOLOGY, 2004, 6 (04) : 329 - 330
  • [33] Polymorphisms in the nucleotide excision repair genes, ERCC1 and ERCC2/XPD and carcinogen DNA adducts in human lung
    Lee, Mi-Sun
    Liu, Chen-yu
    Su, Li
    Wain, John C.
    Mark, Eugene J.
    Christiani, David C.
    [J]. CANCER RESEARCH, 2012, 72
  • [34] Association between ERCC1 C8092A and ERCC2 K751Q polymorphisms and risk of adult glioma: a meta-analysis
    Xu, Zhiqin
    Ma, Wenbin
    Gao, Lu
    Xing, Bing
    [J]. TUMOR BIOLOGY, 2014, 35 (04) : 3211 - 3221
  • [35] Association Between ERCC2 Polymorphisms and Glioma Risk: a Meta-analysis
    Huang, Li-Ming
    Shi, Xi
    Yan, Dan-Fang
    Zheng, Min
    Deng, Yu-Jie
    Zeng, Wu-Cha
    Liu, Chen
    Lin, Xue-De
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (11) : 4417 - 4422
  • [36] Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis
    Liu, Xueyong
    Zhang, Zhan
    Deng, Chunbo
    Tian, Yihao
    Ma, Xun
    [J]. ONCOTARGET, 2017, 8 (37) : 62769 - 62779
  • [37] ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis
    Yin, Ming
    Yan, Jingrong
    Martinez-Balibrea, Eva
    Graziano, Francesco
    Lenz, Heinz-Josef
    Kim, Hyo-Jin
    Robert, Jacques
    Im, Seock-Ah
    Wang, Wei-Shu
    Etienne-Grimaldi, Marie-Christine
    Wei, Qingyi
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (06) : 1632 - 1640
  • [38] ERCC1 rs3212986 and ERCC2 rs13181 gene polymorphisms contributes to the susceptibility to pancreatic cancer in a Chinese population
    Sileng, A.
    Pan, Runhua
    Li, Guanhong
    Wang, Wei
    Li, Jiye
    Zhang, Mao
    Li, Min
    Zhang, Zilang
    Lin, Jing
    Liao, Caixian
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (05): : 5687 - 5693
  • [39] Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population
    Wu, Xiaoqing
    Lu, Wenping
    Jiang, Cuihong
    Zhang, Dongni
    Zhang, Weixuan
    Cui, Yongjia
    Zhuo, Zhili
    Mei, Heting
    Wang, Ya'nan
    Zhang, Mengfan
    Chen, Shuntai
    [J]. PLOS ONE, 2023, 18 (05):
  • [40] Polymorphisms in ERCC2 and ERCC5 and Risk of Prostate Cancer: A Meta-Analysis and Systematic Review
    Liu, Yi
    Hu, Yonghui
    Zhang, Meng
    Jiang, Runze
    Liang, Chaozhao
    [J]. JOURNAL OF CANCER, 2018, 9 (16): : 2786 - 2794